Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

Hepatology

Volumn 37, Issue 5, 2003, Pages 1202-1219

  Neuschwander Tetri, Brent A ^a   Caldwell, Stephen H ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ALCOHOL; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN; BETAINE; BEZAFIBRATE; CLOFIBRATE; CYTOKINE; FATTY ACID; GEMFIBROZIL; HISTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAZAROID; LEPTIN; LIVER ENZYME; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; S ADENOSYLMETHIONINE; TAURINE; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VERY LOW DENSITY LIPOPROTEIN;

AGE; ALCOHOL ABUSE; AUTOPSY; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; ETHNOLOGY; EXERCISE; FATTY LIVER; GASTROPLASTY; GENDER; GENETIC PREDISPOSITION; HEREDITY; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; IMAGING; INSULIN RESISTANCE; INSULIN SENSITIVITY; LABORATORY TEST; LIFESTYLE; LIPID STORAGE; LIPODYSTROPHY; LIPOPROTEIN METABOLISM; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; MALLORY BODY; NON INVASIVE MEASUREMENT; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELIABILITY; RISK FACTOR; STAGING; STOMACH BYPASS; SYMPTOM;

EID: 0038644536     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50193     Document Type: Conference Paper

References (237)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic Proc 1980;55:434-438.
2. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002;22:185-194.
3. Dixon JB, O'Brien PE, Bhatal PS. A wider view on diagnostic criteria of nonalcoholic steatohepatitis (reply). Gastroenterology 2002;122:841-842.
4. Cairns SR, Peters TJ. Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clin Sci 1983;65:645-652.
5. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
6. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48-53.
7. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000;173:476-479.
8. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
9. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750.
10. Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. HEPATOLOGY 1995;21:1742-1743.
11. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
12. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-373.
13. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. HEPATOLOGY 1990;11:74-80.
14. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. HEPATOLOGY 1999;29:664-669.
15. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. HEPATOLOGY 2000;32:689-692.
16. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801.
17. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999;34:85-91.
18. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010-3014.
19. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
20. Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000;95:3206-3210.
21. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. HEPATOLOGY 1996;24:813-815.
22. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population: examination of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977;12:593-597.
23. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.
24. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. HEPATOLOGY 1990;12:1106-1110.
25. Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study. Int J Obes Relat Metab Disord 1984;8:97-106.
26. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes Relat Metab Disord 1984;8:107-115.
27. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
28. Garcia-Monzón C, Martin-Pérez E, Iacono OL, Fernández-Bermejo M, Majano PL, Apolinario A, Larraãga E, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716-724.
29. Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut 1985;26:133-139.
30. Klain J, Fraser D, Goldstein J, Peiser J, Avinoah E, Ovnat A, Charuzi I. Liver histology abnormalities in the morbidly obese. HEPATOLOGY 1989;10:873-876.
31. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594-598.
32. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
33. Falchuk KR, Fiske SC, Haggitt RC, Federman M, Trey C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology 1980;78:535-541.
34. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annual 1989;24:275-302.
35. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, Norris HT, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349-1355.
36. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1999;30:1356-1362.
37. Saksena S, James O, Craig W, Day CP. Clinical and laboratory parameters predicting presence of NASH in unselected patients with NAFLD [Abstract]. HEPATOLOGY 2002;36:222A.
38. Nanji AA, French SW, Freeman JB. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986;36:266-269.
39. Caldwell SH, Hespenheide EE: Obesiry and cryptogenic cirrhosis. In: Leuschner U, James O, Dancygier H, eds. Falk Symposium: Steatohepatitis (ASH and NASH). Volume 121. Norwell, MA: Kluwer Academic Publishers, 2001;151.
40. Propst A, Propst T, Zangerl G, Ofner D, Judmaier G, Vogel W. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci 1995;40:1805-1815.
41. Sasaki A, Horiuchi N, Hasegawa K, Uehara M. Mortality and causes of death in type 2 diabetic patients. A long-term follow-up study in Osaka District, Japan. Diabetes Res Clin Pract 1989;7(Suppl):33-40.
42. Hilden M, Juhl E, Thomsen AC, Christoffersen P. Fatty liver persisting for up to 33 years. A follow-up of the inversen-roholm liver biopsy material. Acta Med Scand 1973;194:485-489.
43. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? [erratum appears in HEPATOLOGY 2002;36:774.] HEPATOLOGY 2002;36:150-155.
44. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
45. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, SayeghTainturier M-H, Giral P, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. HEPATOLOGY 2002;35:1485-1493.
46. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? [Letter; Comment] Gastroenterology 2002;123:375-378.
47. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000;136:727-733.
48. Dulloo AG. Biomedicine. A sympathetic defense against obesity. Science 2002;297:780-781.
49. Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, Lowell BB. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002;297:843-845.
50. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002;97:1496-1500.
51. Santos L, Molina EG, Jeffers LJ, Reddy KR, Schiff ER. Prevalence of nonalcoholic steatohepatitis among ethnic groups [Abstract]. Gastroenterology 2001;120:A117.
52. Squires RH, Lopez MJ. Steatohepatitis is a serious condition in Hispanic children [Abstract]. HEPATOLOGY 2000;32:418A.
53. Kemmer NM, McKinney KH, Xiao S-Y, Singh H, Murray R, Abdo B, Eledrisi M, et al. High prevalence of NASH among Mexican American females with type II diabetes mellitus [Abstract]. Gastroenterology 2001;120:A117.
54. Weston SR, Leyden WA, Murphy R, Manos MM, Bell BP, Bacchetti P, Bass NM, et al. Racial/ethnic distribution of newly diagnosed non-alcoholic fatty liver among participants of the chronic liver disease surveillance study [Abstracr]. HEPATOLOGY 2002;36:405A.
55. Perry AC, Applegate EB, Jackson ML, Deprima S, Goldberg RB, Ross R, Kempner L, et al. Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. J Appl Physiol 2000;89:636-643.
56. Struben VMD, Hespenheide EE, Caldwell S. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108:9-13.
57. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-2961.
58. Lee JH, Rhee PL, Lee JK, Lee KT, Kim JJ, Koh KC, Paik SW, et al. Role of hyperinsulinemia and glucose intolerance in the pathogenesis of nonalcoholic fatty liver in patients with normal body weight. Korean J Intern Med 1998;13:12-14.
59. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137-144.
60. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. HEPATOLOGY 2002;35:367-372.
61. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. HEPATOLOGY 2002;35:373-379.
62. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999;18:353-358.
63. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, Lurie Y, et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73-79.
64. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995;9:101-105.
65. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989-993.
66. Kuczmarski RJ. Need for body composition information in elderly subjects. Am J Clin Nutr 1989;50:1150-1157; discussion 1231-1235.
67. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989;97:1022-1024.
68. Garg A. Lipodystrophies. Am J Med 2000;108:143-152.
69. De Craemer D, Pauwels M, Van den Branden C. Alterations of peroxisomes in steatosis of the human liver: a quantitative study. HEPATOLOGY 1995;22:744-752.
70. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD Jr. Mirochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999;31:430-434.
71. Sanyal AJ, Campbell-Sargent C, Mirshani F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
72. Bohan A, Droogan O, Nolan N, Mayne P, Bonham J, Thornton P, Farrell MA, et al. Mitochondrial DNA abnormalities without significant deficiency of intramitochondrial fatty acid β-oxidation enzymes in a well defined subgroup of patients with nonalcoholic steatohepatitis (NASH) [Abstract]. HEPATOLOGY 2000;32:387A.
73. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69.
74. Wasserman JM, Thung SN, Berman R, Bodenheimer HC Jr, Sigal SH. Hepatic Weber-Christian disease. Semin Liver Dis 2001;21:115-118.
75. Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord 1995;19:S27-S36.
76. Vila MR, Gamez J, Solano A, Playan A, Schwartz S, Santorelli FM, Cervera C, et al. Uncoupling protein-1 mRNA expression in lipomas from patients bearing pathogenic mirochondrial DNA mutations. Biochem Biophys Res Commun 2000;278:800-802.
77. Mansouri A, Gaou I, Fromenty B, Berson A, Letteron P, Degott C, Erlinger S, et al. Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. Gastroenterology 1997;113:599-605.
78. Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers [see comments]. Liver 1999;19:299-304.
79. Redlich CA, West AB, Fleming L, True LD, Cullen MR, Riely CA. Clinical and pathological characteristics of hepatotoxicity associated with occupational exposure to dimethylformamide. Gastroenterology 1990;99:748-757.
80. Cotrim H, Freitas LA, Freitas C, Braga L, Parana R, Lyra L, Carvalho F. Nonalcoholic steatohepatitis in petrochemical workers: follow up of those removed from exposure area and those who remained [Abstract]. HEPATOLOGY 2002;36:983A.
81. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
82. Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984;311:167-172.
83. Cai Q, Bensen M, Greene R, Kirchner J. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol 2000;95:277-279.
84. Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis - report of three cases. J Hepatol 1995;23:95-97.
85. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-820.
86. Dahl MG, Gregory MM, Scheuer PJ. Liver damage due to methotrexate in patients with psoriasis. Br Med J 1971;1:625-630.
87. Cassagnou M, Boruchowicz A, Guillemot F, Gheyssens Y, Devisme L, Cortot A, Colombel JF. Hepatic steatosis revealing celiac disease: a case complicated by transitory liver failure [Letter]. Am J Gastroenterol 1996;91:1291-1292.
88. Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: evolution to micronodular cirrhosis. Gastroenterology 1974;67:107-118.
89. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-9.
90. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001;104:517-529.
91. 13C NMR. Science 1991;254:573-576.
92. 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-1327.
93. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001;98:7522-7527.
94. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
95. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997;389:610-614.
96. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 2001;293:1673-1677.
97. Hundal RS, Petersen KF, Mayerson A, Randhawa P, Inzucchi S, Shoelson SE, Shulman GI. Mechanisms by which high dose aspirin improves fasting and postprandial glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-1326.
98. Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L. Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 1997;100:3105-3110.
99. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. HEPATOLOGY 2002;35:762-771.
100. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002;122:1399-1410.
101. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
102. Kondo M, Shimomura I, Matsukawa Y, Kumada K, Takahashi M, Matsuda M, Ouchi N, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002;51:2325-2328.
103. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953.
104. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-1672.
105. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol 2001;281:G1135-G1139.
106. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther 2001;299:638-644.
107. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 2002;277:17377-17380.
108. Mensenkamp AR, Teusink B, Bailer JF, Wolters H, Havinga R, van Dijk KW, Havekes LM, et al. Mice expressing only the mutant APOE3 Leiden gene show impaired VLDL secretion. Arterioscler Thromb Vasc Biol 2001;21:1366-1372.
109. Davidson NO, Shelness GS. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000;20:169-193.
110. Leung GK, Veniant MM, Kim SK, Zlot CH, Raabe M, Bjorkegren J, Neese RA, et al. A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion. J Biol Chem 2000;275:7515-7520.
111. Bernard S, Touzet S, Personne I, Lapras V, Bondon PJ, Berthezène F, Moulin P. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000;43:995-999.
112. Bjorkegren J, Beigneux A, Bergo MO, Maher JJ, Young SG. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 2002;277:5476-5483.
113. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. HEPATOLOGY 2002;35:898-904.
114. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002;87:3019-3022.
115. Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, Barnes RI, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002;31:21-23.
116. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002;87:408-411.
117. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000;24:153-156.
118. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996;98:1575-1584.
119. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002;277:19353-19357.
120. Arioglu Oral E, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-578.
121. Dianzani MU. Uncoupling of oxidative phosphorylation in mitochondria from fatty livers. Biochim Biophys Acta 1954;14:514-532.
122. Dianzani MU. The content of adenosine polyphosphates in fatty livers. Biochem J 1957;65:116-124.
123. Vendemiale G, Grattagliano I, Caraceni P, Caraccio G, Domenicali M, Dall'Agata M, Trevisani F, et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. HEPATOLOGY 2001;33:808-815.
124. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-1664.
125. Baffy G, Zhang C-Y, Glickman JN, Lowell BB. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. HEPATOLOGY 2002;35:753-761.
126. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. HEPATOLOGY 1997;26:143-146.
127. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:274-280.
128. Day C. CD14 promoter polymorphism associated with risk of NASH. J Hepatol 2002;36(Suppl 1):21.
129. Järveläinen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. HEPATOLOGY 2001;33:1148-1153.
130. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001;21:89-104.
131. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, Mombaerts P, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001;108:1113-1121.
132. Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW, Flier JS. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. Endocrinology 1997;138:3859-3863.
133. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170.
134. Lu SC, Alvarez L, Huang ZZ, Chen L, An W, Corrales FJ, Avila MA, et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci U S A 2001;98:5560-5565.
135. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
136. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002;123:882-932.
137. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-468.
138. Brodkin CA, Daniell W, Checkoway H, Echeverria D, Johnson J, Wang K, Sohaey R, et al. Hepatic ultrasonic changes in workers exposed to perchloroethylene. Occup Environ Med 1995;52:679-685.
139. Redlich CA, Cullen MR. Nonalcoholic steatohepatitis. Ann Intern Med 1997;127:410.
140. Saksena S, Johnson J, Ouiff SP, Elias E. Diet and exercise: important first steps in therapy of NASH [Abstract]. HEPATOLOGY 1999;30:436A.
141. Bertram SR, Venter I, Stewarr RI. Weight loss in obese women - exercise v. dietary education. S Afr Med J 1990;78:15-18.
142. Eden KB, Orleans CT, Mulrow CD, Pender NJ, Teursch SM. Does counseling by clinicians improve physical activity? A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:208-215.
143. Tuomilehro J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
144. Jones NL, Killian KJ. Exercise limitation in health and disease. N Engl J Med 2000;343:632-641.
145. van Baak MA. Exercise training and substrare urilisation in obesity. Inr J Obes Relar Metab Disord 1999;23:S11-S17.
146. Hoppeler H. Skeletal muscle substrate metabolism. Int J Obes Relat Metab Disord 1999;23:S7-S10.
147. Eriksson S, Eriksson K-F, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986;220:83-88.
148. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107.
149. Keeffe EB, Adesman PW, Stenzel P, Palmer RM. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Dig Dis Sci 1987;32:441-445.
150. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in'overweight patients. Gastroenterology 1990;99:1408-1413.
151. Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967;12:198-208.
152. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 1970;282:829-834.
153. Andersen T, Gluud C, Franzmann M-B, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-229.
154. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994;125:239-241.
155. Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000;136:739-743.
156. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002;347:1483-1492.
157. Spieth LE, Harnish JD, Lenders CM, Raezer LB, Pereira MA, Hangen SJ, Ludwig DS. A low-glycemic index diet in the treatment of pediatric obesity. Arch Pediatr Adolesc Med 2000;154:947-951.
158. Vessby B. Dietary fat and insulin action in humans. Br J Nutr 2000;83: S91-S96.
159. Kurihara T, Adachi Y, Yamagata M, Abe K, Akimoto M, Hashimoto H, Ishiguro H, et al. Role of eicosapentaenoic acid in lipid metabolism in the liver, with special reference to experimental fatty liver. Clin Ther 1994;16:830-837.
160. Nanji AA, Sadrzadeh SM, Yang EK, Fogt F, Meydani M, Dannenberg AJ. Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. Gastroenterology 1995;109:547-554.
161. Lokesh B, LiCari J, Kinsella JE. Effect of different dietary triglycerides on liver fatty acids and prostaglandin synthesis by mouse peritoneal cells. JPEN J Parenter Enteral Nutr 1992;16:316-321.
162. Lanza-Jacoby S, Smythe C, Phetteplace H, Tabares A. Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver. JPEN J Parenter Enteral Nutr 1992;16:353-358.
163. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Safety 1999;20:119-131.
164. Harrison SA, Fincke C, Helinski D, Torgerson S. Orlistar treatment in obese, non-alcoholic sreatohepatitis patients: a pilor study [Abstract]. HEPATOLOGY 2002;36:406A.
165. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001;120:669-681.
166. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefébvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Inr J Obes Relat Merab Disord 1998;22:222-226.
167. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995;104:23-31.
168. Ackerman NB. Protein supplementation in the management of degenerating liver function after jejunoileal bypass. Surg Gynecol Obsterr 1979;149:8-14.
169. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass - prevention and reversal by metronidazole, irrespective of proteincalorie malnutrition. Gastroenterology 1982;82:535-548.
170. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. HEPATOLOGY 1996;23:1464-1467.
171. Guma G, Viola L, Thomé M, Galdame O, Alverez E. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial [Abstract]. HEPATOLOGY 1997;26:387A.
172. Ceriani R, Bunati S, Morini L, Sacchi E, Colombo G. Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis (abstract). HEPATOLOGY 1998;28:386A.
173. Mendez-Sanchez N, Gonzalez V, Pichardo-Bahena R, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial [Abstract]. HEPATOLOGY 2002;36:412A.
174. Antosiewicz J, Nishizawa Y, Liu X, Usukura J, Wakabayashi T. Suppression of the hydrazine-induced formation of megamitochondria in the rat liver by alpha-tocopherol. Exp Mol Pathol 1994;60:173-187.
175. Soltys K, Dikdan G, Koneru B. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. HEPATOLOGY 2001;34:13-18.
176. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-738.
177. Alvaro D, Gigliozzi A, Piat C, Carli L, Bini A, La Rosa T, Furfaro S, et al. Effect of S-adenosyl-L-methionine on ethanol cholestasis and hepatotoxicity in isolated perfused rat liver. Dig Dis Sci 1995;40:1592-1600.
178. Lu SC. Methionine adenosyltransferase and liver disease: it's all about SAM. Gastroenterology 1998;114:403-407.
179. Colell A, Garcia-Ruiz C, Morales A, Ballesta A, Ookhtens M, Rodes J, Kaplowitz N, et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. HEPATOLOGY 1997;26:699-708.
180. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-2717.
181. Gulbahar O, Karasu ZA, Ersoz G, Akarca US, Musoglu A. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine [Abstract]. Gastroenterology 2000;118:A1444.
182. Brown BG, Zhao XQ, Chair A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592.
183. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000;28:1270-1273.
184. Fu CS, Esrason K, Alshak NS, Conteas CN, Simmons VJ. Dietary lecithin, anti-oxidant and vitamin B complex (LAB) decrease hepatic steatosis in patients with NASH [Abstract]. Gastroenterology 1998;114: A1243.
185. Azuma Y, Shinohara M, Wang PL, Hidaka A, Ohura K. Histamine inhibits chemotaxis, phagocytosis, superoxide anion production, and the production of TNFalpha and IL-12 by macrophages via H2-receptors. Int Immunopharmacol 2001;1:1867-1875.
186. Villa RF, Gorini A. Pharmacology of lazaroids and brain energy metabolism: a review. Pharm Rev 1997;49:99-136.
187. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002;122:931-939.
188. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
189. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
190. Acosta RC, Molina EG, O'Brien CB, Cobo MC, Amaro R, Neff GW, Schiff ER. The use of pioglitazone in nonalcoholic steatohepatitis [Abstract]. Gastroenterology 2001;120:A546.
191. Neuschwander-Tetri BA, Brunt EM, Bacon BR, Sponseller C, Wehmeier KR, Hampton K. Histological improvement in NASH following increased insulin sensitivity with the PPAR-γ ligand rosiglitazone for 48 weeks [Abstract]. HEPATOLOGY 2002;36:379A.
192. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-1940.
193. Azuma T, Tomita K, Kato S, Adachi M, Inokuchi N, Kitamura N, Nishimura T, et al. A pilot study of a thiazolidinediones, pioglitazone, in nonalcoholic steatohepatitis [Abstract]. HEPATOLOGY 2002;36:406A.
194. Sanyal AJ, Contos MJ, Sargeant C, Stravitz RT, Luketic VA, Sterling RK, Shiffman ML. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis [Abstract]. HEPATOLOGY 2002;36:A382.
195. Vamecq J, Latruffe N. Medical significance of peroxisome proliferatoractivated receptors. Lancet 1999;354:141-148.
196. Ribon V, Johnson JH, Camp HS, Saltiel AR. Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proc Natl Acad Sci U S A 1998;95:14751-14756.
197. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288-293.
198. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997;54:801-808.
199. Aubert J, Champigny O, Saint-Marc P, Negrel R, Collins S, Ricquier D, Ailhaud G. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 1997;238:606-611.
200. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133:263-274.
201. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
202. Coyle WJ, Delaney N, Yoshihashi A, Lawson P. Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology [Abstract]. Gastroenterology 1999;116:A1198.
203. Urso R, Visco-Comandini U. Metformin in non-alcoholic steatohepatitis [Letter]. Lancet 2002;359:355-356.
204. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis [Letter]. Lancet 2001;358:893-894.
205. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
206. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the Stop-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077.
207. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999;48:1836-1841.
208. Nestler JE, Jakubowicz DJ, Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol 2000;13:1295-1298.
209. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis [Letter]. Lancet 1999;353:1802.
210. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [Letter; Comment]. J Hepatol 1999;31:384.
211. Horlander JC, Kwo PY, Cummings OW, Koukoulis G. Atorvastatin for the treatment of NASH [Abstract]. Gastroenterology 2001;120:A544.
212. Nair S, Wiseman M. HMG-CoA reductase inhibitors in no alcoholic fatty liver disease: is their potential hepatotoxicity an issue in these patients? A case control study based on histology [Abstract]. HEPATOLOGY 2002;36:409A.
213. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
214. Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J Hepatol 2001;35:816-822.
215. Czaja AJ. Recurrence of nonalcoholic steatohepatitis after liver transplantation [Editorial]. Liver Transplant Surg 1997;3:185-186.
216. Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transplant Surg 1997;3:177-178.
217. Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transplant Surg 1997;3:174-176.
218. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802-1805.
219. Cassarino DS, Swerdlow RH, Parks JK, Parker WD Jr, Bennett JP Jr. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun 1998;248:168-173.
220. Anonymous. Nonalcoholic Steatohepatitis Clinical Research Network. HEPATOLOGY 2003;37:244.
221. Brunt EM, Janney CJ, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999;94:2467-2474.
222. Sozo A, Arrese M, Glasinovic JC. Evidence of intestinal bacterial overgrowth in patients with NASH [Abstract]. Gastroenterology 2001;120: A118.
223. Bogomolov P, Petrakov A, Vereshagina V, Isakov V. Abnormal hydrogen breath test in patients with NASH [Abstract]. AASLD Syllabus Single Topic Conference Nonalcoholic Steatohepatitis, September 20-22, 2002. Atlanta, GA.
224. Al-Osaimi AMS, Caldwell SH. Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis [Abstract]. HEPATOLOGY 2002;36:408A.
225. Guillausseau P-J, Massin P, Dubois-Laforgue D, Timsit J, Virally M, Gin H, Bertin E, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med 2001;134:721-728.
226. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002;97:2058-2062.
227. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-1062.
228. Nagore N, Scheuer PJ. Does a linear pattern of sinusoidal IgA deposition distinguish between alcoholic and diabetic liver disease? Liver 1988;8:281-286.
229. Tumiel M, Whitcomb BJ, Krawitt EL. Circulating antinuclear antibodies in patients with nonalcoholic steatohepatitis [Abstract]. HEPATOLOGY 1994;20:409A.
230. Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 1997;25:538-540.
231. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421-429.
232. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, et al. Increased hepatic iron in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
233. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. HEPATOLOGY 1999;30:847-850.
234. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001;21:71-80.
235. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428-1432.
236. Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996;403:607-613.
237. Day CP, James OF. Steatohepatitis: a tale of two "hits"? [Editorial] Gastroenterology 1998;114:842-845.